Financial Data and Key Metrics Changes - In 2024, the company recorded $1.2 million in revenue, a growth of 59% over 2023 [28] - Revenue from the NUQ VET cancer test was $0.8 million, growing by 75% compared to the prior year [28] - Operating expenses were reduced by 23% year-on-year, with second-half operating expenses down 31% [30][34] - Net cash used in operating activities was $25.9 million in 2024, compared to $18.1 million in 2023 [31] Business Line Data and Key Metrics Changes - Approximately 120,000 NUQ VET cancer tests were sold in 2024, more than double the prior year [28] - Revenue from the NUQ Discover pillar was approximately $400,000, with year-on-year growth of 40% [29] - The company recorded its first revenue from NUQ NETS, marking a significant milestone [29] Market Data and Key Metrics Changes - The NUQ VET cancer test is now available in over 20 countries, expanding access significantly [18] - The point-of-care market is noted to be less than 20% of the total market, indicating growth potential [22] Company Strategy and Development Direction - The company aims to sign multiple licensing deals in 2025, focusing on human applications [11][68] - There is a strong interest in out-licensing and supply agreements for both NUQ NETS and the oncology portfolio [12][69] - The strategy includes raising non-dilutive funds, ramping revenues, reducing expenses, and signing commercial deals with large industry players [74] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash neutrality on a full-year basis by 2025 [27] - The company is at a pivotal juncture, ready to revolutionize diagnostics for both animals and humans [12] - Management highlighted the importance of automation in centralized labs to accelerate growth [22] Other Important Information - The company received approximately $1.8 million in non-dilutive funding from Belgian institutions during 2024 [33] - Significant progress was made in clinical studies, with multiple large independent studies completed [10][36] Q&A Session Summary Question: Update on the feline cancer testing program - The feline cancer testing program is on track for completion later this year, with a milestone payment of $5 million expected upon completion [80] Question: Discussion on the Leon study and its implementation - The Leon study is expected to lead to prospective studies and potential implementation in screening regimens [85][90] Question: Insights on quarterly sales trends and outlook for 2025 - Sales were volatile due to large customers ordering in batches, but overall growth was solid with 120,000 tests sold [100][102] Question: Approach to managing financing risks - The company plans to maintain tight control over expenses and cash flows while focusing on licensing agreements [112] Question: Activity in data sharing and licensing agreements - The company has established data rooms for oncology and NETS, which have energized discussions with major companies [118][120]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact name of registrant as specified in its charter) 1489 West Warm Springs Road, Suite 110 Delaware (State or other ju ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2025 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification Number) Check the appropriate box below if the Form 8-K filing is intended ...

Cameron Reynolds, President and Group Chief Executive Officer, said: "Our focus in 2024 was on generating sufficient clinical data to convince the biggest players in the diagnostic, screening, and liquid biopsy world that our Nu.Q® platform will play a significant role in both the oncology and sepsis markets. I believe this was achieved beyond our expectations: a range of independent studies demonstrating the value of our platform have been completed. We built impressive data rooms in 2024, and 2025 will se ...

Core Insights - VolitionRx Limited presents two studies at the European Lung Cancer Congress 2025, highlighting the potential of its Nu.Q® H3K27Me3 biomarker combined with circulating tumor DNA to enhance prognostic value for overall survival in Non-Small Cell Lung Cancer (NSCLC) [1] - The studies also showcase Volition's Nu.Q® H3.1, a low-cost immunoassay aimed at early identification of individuals at high risk for cancer [1] Group 1: Event Details - The European Lung Cancer Congress 2025 (ELCC 2025) is held in Paris, France from March 26-29, 2025 [2] - Two poster sessions are scheduled for March 28, 2025, featuring presentations on early detection and prognostic biomarkers in NSCLC [3] Group 2: Company Overview - Volition is a multi-national company focused on advancing epigenetics to improve early detection and monitoring of diseases, including cancer [4] - The company aims to develop cost-effective blood tests to enhance patient outcomes and quality of life through early detection [5] - Volition's research and development activities are primarily based in Belgium, with additional offices in the U.S. and London [6]

HENDERSON, Nev., March 27, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces it will host a virtual investor event on Wednesday, April 9, 2025, at 10:00 AM ET, featuring Volition's Gael Forterre, Chief Commercial Officer, Dr. Andrew Retter, Chief Medical Officer and Dr. Jake Micallef, Chief Scientific Officer. To register, click here.This webinar will provide an overview following the completion of a number of large independent ...

Core Viewpoint - VolitionRx Limited will host a conference call on March 31, 2025, to discuss its financial and operational results for Q4 and the full fiscal year 2024, along with a business update [1][2]. Group 1: Conference Call Details - The conference call is scheduled for March 31, 2025, at 4:30 p.m. U.S. Eastern Time [1][2]. - Dial-in numbers for the call include a toll-free option for the U.S. and Canada at 1-877-407-9716, and an international toll number at 1-201-493-6779 [2]. - The call will be hosted by key executives including the Group Chief Marketing & Communications Officer, the President and Group CEO, the Group CFO, and the Chief Medical Officer [2]. Group 2: Company Overview - Volition is a multinational company focused on advancing epigenetics to improve early detection and monitoring of diseases [4][5]. - The company is developing cost-effective blood tests for various diseases, including certain cancers and conditions related to NETosis, such as sepsis [5]. - Research and development activities are primarily based in Belgium, with additional facilities in the U.S. and London [5].

Volition study shows rapid, low-cost, automated Nu.Q® Cancer test accurately detects human cancers at high specificityHENDERSON, Nev., March 21, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ('Volition'), a multi-national epigenetics company, today announces the results of a study which shows that an automated Nu.Q® Cancer immunoassay test in development detected a range of 21 different cancers. This could potentially be used as a standalone pan-cancer test or, given its low false positive r ...

Core Viewpoint - VolitionRx Limited aims to transform the lung cancer diagnosis and monitoring landscape with its Nu.Q® Cancer Test, targeting the $4 billion lung cancer market [1][4]. Company Overview - VolitionRx Limited is a multi-national epigenetics company focused on advancing early detection and monitoring of diseases, including cancer [6][7]. - The company is developing cost-effective blood tests that can be administered easily, utilizing small blood samples [1][7]. Product Development - The Nu.Q® Cancer assays are designed to improve early detection and monitoring of lung cancer, potentially enhancing patient outcomes [1][3]. - A retrospective study involving 1,050 patients with Non-Small Cell Lung Cancer is set to be published, supporting the efficacy of Nu.Q® Cancer [4]. Market Opportunity - The total annual accessible market for lung cancer screening, prognostication, and minimal residual disease identification is estimated at approximately $4 billion [4]. - VolitionRx is in discussions with large diagnostics and liquid biopsy companies to establish multiple licensing agreements this year [4]. Commercial Strategy - The company's nucleosome assays can be utilized on existing automated chemiluminescence platforms, eliminating the need for new hardware [5]. - VolitionRx aims to make Nu.Q® Cancer testing widely accessible through licensing and partnership arrangements [5].

Volition to host multiple presentations at the International Symposium on Intensive Care & Emergency Medicine in Brussels, Belgium, from March 18 - 21 HENDERSON, Nev., March 17, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced its participation at the 44th Annual ISICEM  ("International Symposium on Intensive Care & Emergency Medicine") Congress in Brussels Belgium being held from March 18-21. As a silver sponsor, Volition will suppo ...